Skip to content 
Recently, the Nanjing Shengde Medical Technology Co., Ltd. (hereinafter referred to as “Shengde Medical”), an enterprise in Jiangbei New District, completed its B+ round of financing. The investors included Nanjing Venture Capital Group, Ruihua Holdings and Jiangbei Science and Technology Investment.
Shengde Medical was established in April 2019. After seven years of development, it has grown into a new force in the industry.
Just one month ago, Shengde Medical reached a milestone in its development – the Xcor™ transcatheter aortic valve replacement system independently developed by the team was officially approved for market launch by the National Medical Products Administration.
At that time, Ma Chenming, the chairman of Shengde Medical, wrote: “In Germany, when marking a tick, it is written as an ‘X’ – not to indicate negation, but rather ‘I have chosen it’. COR, in Latin, means ‘heart’. Xcor™ is ‘born for the heart’.”
Ma Chenming is a typical highly educated returnee from overseas. He graduated from the Medical Department of Peking University and went to Germany for further studies in 2010. He obtained a German medical license and later worked at the Munich Heart Center – the national cardiovascular disease center of Germany. The most distinctive feature of this center is minimally invasive heart surgeries.
During his time in Germany, Ma Chenming was deeply moved by seeing many Chinese patients traveling long distances to seek medical treatment there – when will Chinese people be able to receive treatment for heart diseases in their own country with ease?
With this aspiration in mind, in 2019, Ma Chenming gave up his job in Berlin and came to Nanjing to establish Shengde Medical, determined to develop valve products suitable for the Chinese population.
Heart valves are a star sector in the medical industry, and the aortic valve is the core area of competition among heart valves.
Currently, aortic valve stenosis is a common “silent killer of the heart” among the elderly. As people age, the aortic valve gradually becomes calcified and narrowed, causing obstruction to the heart’s blood pumping, and in severe cases, it can lead to heart failure and sudden death, posing a threat to life.
The transcatheter aortic valve replacement (TAVR), as the core method of minimally invasive treatment, does not require an open chest operation and can complete valve replacement through minimally invasive intervention. It has already become the preferred treatment option for elderly and high-risk patients.
However, in clinical practice, complex anatomical structures and postoperative complications have always been “obstacles” that have troubled doctors and patients.
Shengde Medical’s Xcor™ has been targeting these pain points since its inception.
It is reported that the approval of Xcor™ has further enriched the domestic TAVR product portfolio. Its innovative design for complex anatomical structures, which is differentiated and complementary to the already approved products, marks that China has added another “domestic alternative” product in the field of transcatheter aortic valve replacement that can rival international standards.
As of April 2026, the Chinese market for heart valve diseases is in a period of rapid development, especially in the field of interventional treatment for structural heart diseases, which exhibits high growth, high competition and high innovation characteristics.
Industry data shows that the market size of TAVR in China was approximately 1.61 billion yuan in 2022, and is expected to reach 11.36 billion yuan by 2030, with a compound annual growth rate (CAGR) of 27.7%.
Currently, the global TAVR field is jointly dominated by international giants and emerging domestic enterprises, and the competition pattern features “international dominance and domestic rise”. This successful financing will help Shengde Medical further delve into the specialized field and actively participate in market competition.
In the future, Shengde Medical will continue to uphold the principle of “using technology to do good deeds and showing compassion in medicine”, with continuous technological innovation and intelligent diagnosis and treatment solutions, to bring hope and vitality to more patients with cardiovascular diseases.
